TMDX Stock Recent News
TMDX LATEST HEADLINES
TransMedics (TMDX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
TransMedics Group, Inc. (NASDAQ:TMDX ) Q1 2024 Earnings Conference Call April 30, 2024 4:30 PM ET Company Participants Laine Morgan - Gilmartin Group, Investor Relations Waleed Hassanein - President & Chief Executive Officer Stephen Gordon - Chief Financial Officer Conference Call Participants Allen Gong - JPMorgan Josh Jennings - TD Cowen Suraj Kalia - Oppenheimer & Company Operator Good afternoon and welcome to the TransMedics First Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
TransMedics (TMDX) came out with quarterly earnings of $0.35 per share, beating the Zacks Consensus Estimate of a loss of $0.05 per share. This compares to loss of $0.08 per share a year ago.
Besides Wall Street's top -and-bottom-line estimates for TransMedics (TMDX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.
In the latest trading session, TransMedics (TMDX) closed at $88.88, marking a -1.9% move from the previous day.
TransMedics (TMDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In the closing of the recent trading day, TransMedics (TMDX) stood at $84.74, denoting a +0.69% change from the preceding trading day.
TransMedics (TMDX) reachead $91.82 at the closing of the latest trading day, reflecting no change compared to its last close.
Whether you believe them or not, analyst ratings have long been a strong indicator of the stock price's direction. There is a direct correlation between how Wall Street analysts rate a stock and how it performs.
FY2023: TransMedics' revenues up 159%, profitability improves, breakeven could be on the horizon. Potential 2x top-line growth medium term in the U.S. alone. TransMedics' Organ Care System (OCS) could drive transplant volumes by expanding the donor pool through increased utilization of marginal (including DCD) organs. As the only FDA-approved multi-organ platform, TransMedics faces relatively limited competition at the moment and looks well positioned to establish a market leading position.